Coya Therapeutics Inc Revenue Growth Rates (COYA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Coya Therapeutics Inc   (NASDAQ: COYA)
 

COYA's Revenue Growth by Quarter and Year

Coya Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

COYA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.24
1st Quarter March 0.25
FY 0.49





COYA Revenue second quarter 2026 Y/Y Growth Comment
Coya Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue rise of 52.34% year on year, to $ 0.24 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue growth. While Coya Therapeutics Inc ' s Revenue jump of 52.34% ranks overall at the positon no. 168 in the second quarter 2026.


COYA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June 52.34 % -95.34 % - -
1st Quarter March -3.85 % 100 % - -
FY   - 123.03 % -40.67 % -

Financial Statements
Coya Therapeutics Inc 's second quarter 2026 Revenue $ 0.24 millions COYA's Income Statement
Coya Therapeutics Inc 's second quarter 2025 Revenue $ 0.16 millions Quarterly COYA's Income Statement


COYA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 11.24 % - -
3rd Quarter September - 2125 % - -
2nd Quarter June -2.5 % -38.46 % 2538.46 % -
1st Quarter March -93.69 % - -97.83 % -
FY (Year on Year)   - 123.03 % -40.67 % -


Back to COYA Growth rate Comparisons >> Back to COYA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #48
Overall #168

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #48
Overall #168
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Coya Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13111.27 % 1941.14 % -100 %
(Mar 31 2025)  


COYA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Coya Therapeutics Inc disclosed fall in Revenue from the first quarter by -2.5% to $ 0.24 millions, from $ 0.25 millions achived in the previous reporting period.

But that's not important problem, as Coya Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Coya Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2384.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #299
Overall #2384
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #299
Overall #2384
Revenue Q/Q Growth Statistics
High Average Low
13111.27 % 1941.14 % -100 %
(Mar 31 2025)  


COYA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Coya Therapeutics Inc disclosed fall in Revenue from the first quarter by -2.5% to $ 0.24 millions, from $ 0.25 millions achived in the previous reporting period.

But that's not important problem, as Coya Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Coya Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2384.


Coya Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 8.02 $ 7.94 $ 7.95 $ 3.99 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 1.01 % -0.08 % 99.26 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 168 # 439 # 0 # 0 # 0


Cumulative Revenue growth Comment
Coya Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 52.34% year on year, to $ 8 millions if the fiscal year would have ended in Jun 30 2026.
Coya Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Coya Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 1.01 % from $7.94 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Coya Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 48
S&P 500 # 168
Cumulative Revenue growth Comment
Coya Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 52.34% year on year, to $ 8 millions if the fiscal year would have ended in Jun 30 2026.
Coya Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Coya Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 1.01 % from $7.94 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 1.01 % increase from $7.94 millions in the period from Mar 31 2026 to Jun 30 2025.

Coya Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 48
S&P 500 # 168




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
COYA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions


About Coya Therapeutics Inc Revenue Growth Rates (COYA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Coya Therapeutics Inc (CIK 1835022).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-343481
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Coya Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.